Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated December 01, 2025, titled "Sun Pharma introduces its global innovative drug, Ilumya® inIndia for treatment of moderate-to-severe Plaque Psoriasis".
Press Release Dec 01 2025
Filed with NSE · · 4 pages · English
Release
Sun Pharmaceutical Industries Limited on 6ix
Earlier from Sun Pharmaceutical Industries
- Press Release Nov 26 2025
- FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)
- Press Release Nov 17 2025
- Press Release Nov 12 2025
- Sun Pharma Canada Inc. Acquires Commercial Rights to LEVULAN® KERASTICK®
Later from Sun Pharmaceutical Industries
- Sun Pharma Launches ILUMYA® In India
- ILUMYA® (tildrakizumab) Pen (Auto-Injector) Now Available for Canadians Living with Moderate-to-Severe Plaque Psoriasis
- Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
- Press Release Jan 15 2026
- Sun Pharma Announces the Availability of UNLOXCYT for Advanced Cutaneous Squamous Cell Carcinoma
Follow Sun Pharmaceutical Industries into a list and get an email when it puts out news.
Follow Sun Pharmaceutical Industries